Insight

Francesco Cribari: Not Every Patient With Elevated Troponin on ICIs Needs a Hospital Bed

Francesco Cribari/LinkedIn

Aug 4, 2025, 17:00

Francesco Cribari: Not Every Patient With Elevated Troponin on ICIs Needs a Hospital Bed

Francesco Cribari, Cardiologist and Cardio-oncologist at Immaculate Conception Dermatological Institute, shared a post on LinkedIn about a recent article he and his colleagues co-authored:

“Not every patient with elevated troponin on immune checkpoint inhibitors (ICIs) needs a hospital bed.

Traditionally, ICI-myocarditis has been perceived as a rare but fulminant condition with a 50% mortality rate.

We’re proud to share our newly published work The FAST TRACK ICI: In our prospective study of 175 referrals — most triggered by mild symptoms or biomarker elevation — we found that:

Most cases were low-risk and manageable without hospital admission
No cardiovascular deaths occurred at 30 days
Over 80% were safely managed through outpatient evaluation
ICI-myocarditis often presents as a smoldering, indolent form — not requiring immediate, aggressive treatment

Our triage algorithm relied on simple clinical parameters:

Absence of CV symptoms
Normal ECG
No history of CV or autoimmune disease
No double ICI therapy

Our criteria supported a pragmatic, stepwise approach to suspected ICI-related cardiotoxicity balancing safety, diagnostic precision, and system adaptability and overall allowing safe outpatient evaluation with advanced diagnostics (e.g., CMR, biopsy) performed within days, rather than emergently.

Thank you to the dedicated teams and all the authors at Institut Mutualiste Montsouris, Institut Curie, and Georges Pompidou European Hospital for their collaboration.”

Title: Cardiovascular safety of a standardized outpatient triage and diagnostic approach for suspected cardiovascular immune-related adverse events of immune checkpoint inhibitors

Authors: Francesco Cribari, Imen Hamdi, Soledad Henriquez, Marie-Liesse Joulia, Pierre Charles, Raphael Colle, Delphine Loirat, Nicolas Girard, Agnes Lillo-Le Louet, Christophe Caussin, Mariana Mirabel

Read the Full Article on Archives of Cardiovascular Diseases

Francesco Cribari: Not Every Patient With Elevated Troponin on ICIs Needs a Hospital Bed

More posts featuring Immune checkpoint inhibitors.

Agnes Lillo-Le Louet cancer Christophe Caussin Delphine Loirat Francesco Cribari Imen Hamdi Immune Checkpoint Inhibitors Mariana Mirabel Marie-Liesse Joulia Nicolas Girard OncoDaily Oncology Pierre Charles Raphael Colle Soledad Henriquez

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Writer?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen

Top 10 Immunotherapy Trials in Lung Cancer to Watch at ESMO 2025

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...